Given the critical role of FKBP52 in AR signaling in cellular and whole animal models, both in vitro and in vivo, FKBP52 has emerged as a potential target for the treatment of prostate cancer (De Leon et al., 2011; Guy et al., 2015; Storer Samaniego et al., 2015; Yong et al., 2007). This evidence concerns the gene FKBP4 and prostate cancer.